Biogen Plans Leases Laboratory-Operations Center In Cambridge, Massachusetts
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and hematologic disorders, and is among the largest and fastest growing global life science companies based in Massachusetts. It will use this new space to expand its drug discovery efforts in this core life science district.
With the lease of the fifth floor to Biogen, BioMed Realty has fully leased the 417,000 square foot 301 Binney Street property. Biogen joins Ironwood Pharmaceuticals and Living Proof located at this prime laboratory and office building.
"BioMed Realty is pleased to welcome Biogen to our growing list of tenants in Cambridge, and we look forward to building a long relationship with such a strong player in the Kendall Square research community," said Bill Kane, Senior Vice President for BioMed Realty in Boston/Cambridge. "We are seeing a growing demand for life science real estate, especially quality laboratory space, here in Cambridge, and we are focused on developing and leasing this unique type of real estate to companies like Biogen, Baxter Healthcare and the growing number of new biotech companies seeking to develop breakthrough therapies in strategic locations."
The lease of 80,000 square feet with Biogen comes after recent announcements of leases to Reed Elsevier and Akamai Technologies totaling just over 100,000 square feet at the recently renovated 50 Hampshire property. These leases reflect the strong demand for lab and office space in Cambridge market, BioMed officials said.
Why are Foreign Trade Zones Making a Comeback?
The New Normal in the Automotive Supply Chain
2020 Auto/Aero Site Guide
Infrastructure Investment as an Economic Stimulus Tool
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Nondisclosure Agreements Best Practices When Negotiating Incentives
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row